$CSTL
Castle Biosciences Inc Stock $cstl

$cstl Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000144736220000257 Filed on November 09, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q3
Revenue	$17.30M	$15.22M	$14.77M
YoY Change	-1.91%	3.0%	298.01%
Cost Of Revenue	$2.670M	$2.475M	$1.708M
YoY Change	32.84%	44.91%	26.44%
Gross Profit	$14.63M	$12.74M	$13.07M
YoY Change	-6.39%	-2.48%	453.41%
Gross Profit Margin	84.55%	83.74%	88.44%
Selling, General & Admin	$14.93M	$11.70M	$7.122M
YoY Change	51.88%	64.32%	81.76%
% of Gross Profit	102.08%	91.85%	54.51%
Research & Development	$4.560M	$3.058M	$1.515M
YoY Change	44.3%	101.85%	17.05%
% of Gross Profit	31.18%	24.0%	11.59%
Depreciation & Amortization	$160.0K	$119.0K	$91.00K
YoY Change	60.0%	30.77%	22.12%
% of Gross Profit	1.09%	0.93%	0.7%
Operating Expenses	$17.66M	$14.76M	$8.637M
YoY Change	35.74%	70.91%	65.69%
Operating Profit	-$3.034M	-$3.901M	$4.429M
YoY Change	-216.07%	-188.08%	-255.31%
Interest Expense	-$380.0K	$706.0K	$1.088M
YoY Change	-22.45%	-35.11%	91.29%
% of Operating Profit			24.57%
Other Income/Expense, Net	$0.00	$0.00	-$2.711M
YoY Change		-100.0%	6234.7%
Pretax Income	-$4.810M	-$4.590M	$5.850M
YoY Change	-325.82%	-178.46%	-269.57%
Income Tax	$80.00K	$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$4.889M	-$4.589M	$5.849M
YoY Change	-337.91%	-178.46%	-269.54%
Net Earnings / Revenue	-28.26%	-30.16%	39.59%
Basic Earnings Per Share	-$0.23	-$0.23	$0.43
Diluted Earnings Per Share	-$0.23	-$0.23	$0.05
COMMON SHARES
Basic Shares Outstanding	19.91M shares	19.94M shares	12.76M shares
Diluted Shares Outstanding		19.94M shares	14.30M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$409.9M	$183.1M	$94.50M
YoY Change	314.88%	93.76%
Cash & Equivalents	$409.9M	$183.1M	$94.47M
Short-Term Investments
Other Short-Term Assets	$4.800M	$3.700M	$2.200M
YoY Change	140.0%	68.18%
Inventory	$2.217M	$1.679M	$821.7K
Prepaid Expenses
Receivables	$12.76M	$12.62M	$12.37M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$429.6M	$201.1M	$109.9M
YoY Change	268.18%	83.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.102M	$6.646M	$1.798M
YoY Change	244.76%	269.58%
Goodwill
YoY Change
Intangibles			$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.536M	$1.638M	$87.17K
YoY Change	1037.78%	1779.13%
Total Long-Term Assets	$9.734M	$9.329M	$3.337M
YoY Change	217.59%	179.54%
TOTAL ASSETS
Total Short-Term Assets	$429.6M	$201.1M	$109.9M
Total Long-Term Assets	$9.734M	$9.329M	$3.337M
Total Assets	$439.3M	$210.4M	$113.2M
YoY Change	266.88%	85.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.098M	$2.101M	$1.251M
YoY Change	12.49%	67.91%
Accrued Expenses	$12.10M	$9.800M	$4.600M
YoY Change	61.33%	113.04%
Deferred Revenue	$6.615M	$8.350M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$10.00M	$3.333M
YoY Change	-100.0%	200.0%
Total Short-Term Liabilities	$20.88M	$30.24M	$9.238M
YoY Change	36.54%	227.35%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$12.46M	$21.57M
YoY Change	-100.0%	-42.26%
Other Long-Term Liabilities	$1.026M	$1.100M	$100.0K
YoY Change	926.0%	1000.0%
Total Long-Term Liabilities	$1.026M	$12.46M	$21.57M
YoY Change	-94.68%	-42.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.88M	$30.24M	$9.238M
Total Long-Term Liabilities	$1.026M	$12.46M	$21.57M
Total Liabilities	$23.64M	$43.84M	$30.86M
YoY Change	-31.75%	42.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$62.50M	-$57.61M	-$54.30M
YoY Change	19.7%	6.09%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$415.7M	$166.6M	$82.34M
YoY Change
Total Liabilities & Shareholders Equity	$439.3M	$210.4M	$113.2M
YoY Change	266.88%	85.86%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	-$4.889M	-$4.589M	$5.849M
YoY Change	-337.91%	-178.46%	-269.54%
Depreciation, Depletion And Amortization	$160.0K	$119.0K	$91.00K
YoY Change	60.0%	30.77%	22.12%
Cash From Operating Activities	-$430.0K	-$2.950M	$750.0K
YoY Change	-109.56%	-493.33%	-140.11%
INVESTING ACTIVITIES
Capital Expenditures	-$590.0K	-$1.900M	-$170.0K
YoY Change	68.57%	1017.65%	88.89%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$590.0K	-$1.900M	-$170.0K
YoY Change	68.57%	1017.65%	88.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	227.8M	8.150M	76.42M
YoY Change	98952.17%	-89.34%	190950.0%
NET CHANGE
Cash From Operating Activities	-430.0K	-2.950M	750.0K
Cash From Investing Activities	-590.0K	-1.900M	-170.0K
Cash From Financing Activities	227.8M	8.150M	76.42M
Net Change In Cash	226.8M	3.300M	77.00M
YoY Change	5078.08%	-95.71%	-4110.42%
FREE CASH FLOW
Cash From Operating Activities	-$430.0K	-$2.950M	$750.0K
Capital Expenditures	-$590.0K	-$1.900M	-$170.0K
Free Cash Flow	$160.0K	-$1.050M	$920.0K
YoY Change	-96.7%	-214.13%	-151.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001447362
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38984
	dei	Entity Registrant Name EntityRegistrantName	CASTLE BIOSCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0701774
	dei	Entity Address Address Line1 EntityAddressAddressLine1	820 S. Friendswood Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 201
	dei	Entity Address City Or Town EntityAddressCityOrTown	Friendswood
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Local Phone Number LocalPhoneNumber	788-9007
	dei	City Area Code CityAreaCode	866
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77546
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	CSTL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19911225	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	183050000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98845000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12618000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14648000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	1679000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	1237000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3718000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1951000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	201065000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	116681000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	1045000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	870000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6646000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2060000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1638000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	135000	USD
CY2020Q3	us-gaap	Assets Assets	210394000	USD
CY2019Q4	us-gaap	Assets Assets	119746000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2101000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1865000	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6354000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5779000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8350000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3435000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1812000	USD
CY2020Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	10000000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5833000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	30240000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15289000	USD
CY2020Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	12455000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19289000	USD
CY2020Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1140000	USD
CY2019Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	55000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	43835000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	34633000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2019Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19844426	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19844426	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17130907	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17130907	shares
CY2020Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	20000	USD
CY2019Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	17000	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	224146000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	137308000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57607000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52212000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	166559000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	85113000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	210394000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	119746000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15217000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14774000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45350000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34230000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2475000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1708000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7012000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5299000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	12742000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	13066000	USD
	us-gaap	Gross Profit GrossProfit	38338000	USD
	us-gaap	Gross Profit GrossProfit	28931000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3058000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1515000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8675000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4226000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11703000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7122000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33173000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19990000	USD
CY2020Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1882000	USD
CY2019Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	0	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	0	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	0	USD
CY2020Q3	cstl	Operating Expenses Net Of Other Operating Loss OperatingExpensesNetOfOtherOperatingLoss	16643000	USD
CY2019Q3	cstl	Operating Expenses Net Of Other Operating Loss OperatingExpensesNetOfOtherOperatingLoss	8637000	USD
	cstl	Operating Expenses Net Of Other Operating Loss OperatingExpensesNetOfOtherOperatingLoss	41848000	USD
	cstl	Operating Expenses Net Of Other Operating Loss OperatingExpensesNetOfOtherOperatingLoss	24216000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3901000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	4429000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3510000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	4715000	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000	USD
CY2019Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	354000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	32000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	706000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	1088000	USD
	us-gaap	Interest Expense InterestExpense	2239000	USD
	us-gaap	Interest Expense InterestExpense	3805000	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	5213000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	5213000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2711000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2933000	USD
CY2020Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-4589000	USD
CY2019Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	5849000	USD
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-5395000	USD
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	3222000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4589000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-4589000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	5849000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5849000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5395000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5395000	USD
	us-gaap	Net Income Loss NetIncomeLoss	3222000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3222000	USD
CY2020Q3	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2019Q3	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	289000	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	2156000	USD
CY2020Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2019Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	17000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	130000	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4589000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5543000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5395000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	936000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.17
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19936000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12758000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18290000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5649000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19936000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14302000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18290000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5747000	shares
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	-50204000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	229000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	747000	USD
CY2019Q3	cstl	Temporary Equity Value Exercise Of Warrants TemporaryEquityValueExerciseOfWarrants	0	USD
CY2019Q3	cstl	Temporary Equity Value Exercise Of Warrants TemporaryEquityValueExerciseOfWarrants	0	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	15265000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	65931000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	26578000	USD
CY2019Q3	cstl	Conversion Of Convertible Preferred Stock To Common Stock Value ConversionOfConvertiblePreferredStockToCommonStockValue	46743000	USD
CY2019Q3	cstl	Reclassifications Of Liability To Permanent Equity ReclassificationsOfLiabilityToPermanentEquity	1745000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	536000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1164000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	5849000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	82336000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	157622000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2118000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	292000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	693000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10423000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-4589000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	166559000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-56566000	USD
	cstl	Temporary Equity Value Exercise Of Warrants TemporaryEquityValueExerciseOfWarrants	0	USD
	cstl	Temporary Equity Value Exercise Of Warrants TemporaryEquityValueExerciseOfWarrants	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	8378000	USD
	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	15265000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	65931000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	26578000	USD
	cstl	Conversion Of Convertible Preferred Stock To Common Stock Value ConversionOfConvertiblePreferredStockToCommonStockValue	46743000	USD
	cstl	Reclassifications Of Liability To Permanent Equity ReclassificationsOfLiabilityToPermanentEquity	1745000	USD
	us-gaap	Net Income Loss NetIncomeLoss	3222000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	82336000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	85113000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5348000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	693000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1296000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	79504000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5395000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	166559000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5395000	USD
	us-gaap	Net Income Loss NetIncomeLoss	3222000	USD
	us-gaap	Depreciation Depreciation	312000	USD
	us-gaap	Depreciation Depreciation	254000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5348000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	536000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	666000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1691000	USD
	cstl	Other Non Cash Interest OtherNonCashInterest	0	USD
	cstl	Other Non Cash Interest OtherNonCashInterest	442000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	5213000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	619000	USD
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	USD
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-237000	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-2077000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1855000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-801000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1767000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1522000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	442000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-61000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1503000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	20000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	211000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-47000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	575000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-895000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	8350000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1709000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	263000	USD
	cstl	Increase Decreasein Deferred Lease Liability IncreaseDecreaseinDeferredLeaseLiability	373000	USD
	cstl	Increase Decreasein Deferred Lease Liability IncreaseDecreaseinDeferredLeaseLiability	12000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10295000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2522000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4162000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	590000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4160000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-590000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	79504000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	65935000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	49000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	4756000	USD
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0	USD
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	11695000	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	9236000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	1776000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	3333000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	1791000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	692000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1164000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1207000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	78070000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	88064000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	84205000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	89996000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98845000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4479000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	183050000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94475000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	32000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	17000	USD
	cstl	Property And Equipment Acquired With Tenant Improvement Allowance PropertyAndEquipmentAcquiredWithTenantImprovementAllowance	714000	USD
	cstl	Property And Equipment Acquired With Tenant Improvement Allowance PropertyAndEquipmentAcquiredWithTenantImprovementAllowance	0	USD
	cstl	Offering Costs And Debt Issuance Costs Incurred But Not Yet Paid OfferingCostsAndDebtIssuanceCostsIncurredButNotYetPaid	0	USD
	cstl	Offering Costs And Debt Issuance Costs Incurred But Not Yet Paid OfferingCostsAndDebtIssuanceCostsIncurredButNotYetPaid	4000	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	46743000	USD
	cstl	Conversion Of Preferred Stock Warrants Amount Issued ConversionOfPreferredStockWarrantsAmountIssued	0	USD
	cstl	Conversion Of Preferred Stock Warrants Amount Issued ConversionOfPreferredStockWarrantsAmountIssued	1745000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	26578000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	183100000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	5213000	USD
CY2020Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of property and equipment, and contingent liabilities. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. The Company has considered the potential impact of the COVID-19 pandemic on its estimates and assumptions. The extent to which the COVID-19 pandemic may impact the Company’s estimates in future periods is uncertain and subject to change.
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	cstl	Contract With Customer Customer Payment Terms ContractWithCustomerCustomerPaymentTerms	P30D
CY2020Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	1450000	USD
CY2019Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	3203000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	223000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	2394000	USD
CY2020Q2	cstl	Centers For Medicare And Medicaid Services Accelerated And Advanced Payment Program Payment Received CentersForMedicareAndMedicaidServicesAcceleratedAndAdvancedPaymentProgramPaymentReceived	8300000	USD
	cstl	Revenue From Contract With Customer Revenue Not Yet Recognized Number Of Claims In Adjudication Process RevenueFromContractWithCustomerRevenueNotYetRecognizedNumberOfClaimsInAdjudicationProcess	2698	claim
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020Q2	us-gaap	Other Operating Income OtherOperatingIncome	1900000	USD
CY2019Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	5213000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020Q3	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	4611000	USD
CY2019Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	4785000	USD
CY2020Q3	cstl	Deferred Payroll Taxes Cares Act DeferredPayrollTaxesCARESAct	378000	USD
CY2020Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2000000	shares
CY2020Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	300000	shares
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4589000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5543000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5395000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	936000	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	420000	USD
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	420000	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4589000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	750000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5395000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3857000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19936000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12758000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18290000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5649000	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	290000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	98000	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	67000	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2903000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19936000	shares
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.43
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1187000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14302000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18290000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5747000	shares
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.17
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2020Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8144000	USD
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2799000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2871000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8215000	shares
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3263000	USD
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1498000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1203000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6646000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2060000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	119000	USD
CY2019Q3	us-gaap	Depreciation Depreciation	91000	USD
	us-gaap	Depreciation Depreciation	312000	USD
	us-gaap	Depreciation Depreciation	254000	USD
CY2020Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2019Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	79000	USD
CY2020Q3	cstl	Accrued Provider Relief Funds AccruedProviderReliefFunds	1882000	USD
CY2019Q4	cstl	Accrued Provider Relief Funds AccruedProviderReliefFunds	0	USD
CY2020Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1201000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1162000	USD
CY2020Q3	us-gaap	Interest Payable Current InterestPayableCurrent	154000	USD
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	184000	USD
CY2020Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	128000	USD
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	218000	USD
CY2020Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	70000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	169000	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3435000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1812000	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-2077000	USD
CY2019Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-2077000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.08
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	84322	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	863127	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2637966	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	856545	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	577120	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	577120	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	38.93
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	332065	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	84322	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	27.02
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1226874	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2798699	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.50
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M25D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	89406000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	635351	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.11
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y29D
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	30076000	USD
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	82624	shares
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.39
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2118000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	229000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5348000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	536000	USD

Files In Submission

Name	View Source	Status
0001447362-20-000257-index-headers.html	Edgar Link	pending
0001447362-20-000257-index.html	Edgar Link	pending
0001447362-20-000257.txt	Edgar Link	pending
0001447362-20-000257-xbrl.zip	Edgar Link	pending
cstl-20200930.htm	Edgar Link	pending
cstl-20200930.xsd	Edgar Link	pending
cstl-20200930_cal.xml	Edgar Link	unprocessable
cstl-20200930_def.xml	Edgar Link	unprocessable
cstl-20200930_htm.xml	Edgar Link	completed
cstl-20200930_lab.xml	Edgar Link	unprocessable
cstl-20200930_pre.xml	Edgar Link	unprocessable
exhibit101-q32020.htm	Edgar Link	pending
exhibit311-q32020.htm	Edgar Link	pending
exhibit312-q32020.htm	Edgar Link	pending
exhibit321-q32020.htm	Edgar Link	pending
exhibit322-q32020.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSTL
Castle Biosciences Inc Stock $cstl

2020 Q4 Form 10-Q Financial Statement

#000144736220000257 Filed on November 09, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSTL Castle Biosciences Inc Stock $cstl

2020 Q4 Form 10-Q Financial Statement

#000144736220000257 Filed on November 09, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSTL
Castle Biosciences Inc Stock $cstl